Clinical Trials Directory

Trials / Completed

CompletedNCT03176225

Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair

Random, Controlled, Single-blinded, Multi-center and Non-inferiority Clinical Study to Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
142 (actual)
Sponsor
LeMaitre Vascular · Industry
Sex
All
Age
6 Years
Healthy volunteers
Not accepted

Summary

The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.

Detailed description

The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial. There will be 144 subjects enrolled, including 72 subjects in the trial arm and 72 subjects in the control arm.

Conditions

Interventions

TypeNameDescription
PROCEDUREOpen heart surgery to address the heart diseaseThe patient will first have open heart surgery to achieve access to the diseased site in the heart
DEVICEClose the defects with XenoSure PatchThe heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
DEVICEClose the defects with Chest Polyester PatchThe heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.

Timeline

Start date
2017-08-15
Primary completion
2020-11-15
Completion
2024-02-15
First posted
2017-06-05
Last updated
2025-03-10

Locations

1 site across 1 country: China

Regulatory

Source: ClinicalTrials.gov record NCT03176225. Inclusion in this directory is not an endorsement.